Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://carlysunx195931.blogkoo.com/retatrutide-australia-a-new-hope-for-obesity-treatment-62594966